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The Unmet Eye Care Needs in
Diabetic Patients on Hemodialysis
Type-2 diabetic nephropathy is a common
cause of increasing prevalence and
incidence of end-stage renal disease
(ESRD).1 Diabetic nephropathy results from
damaged vessels that filter wastes. As the
disease progresses, type-2 diabetic patients
with ESRD, can develop retinopathy. The
Trial to Reduce Cardiovascular Events
with Aranesp Therapy (TREAT) showed
that retinopathy was present in 47% of
individuals with type 2 diabetes, chronic
kidney disease (CKD) and anemia.2
Despite the potential for retinopathy,
diabetes patients with ESRD underutilize eye
care services. A study showed that only 25%
of hemodialysis patients with diabetes had
annual eye exams, yet diabetic retinopathy
was found in 45% of the patients of the
cohort.3 Due to the nature of the disease,
individuals tend not to seek eye care
because they are symptom-free until they
experience significant vision impairment.
Additionally, hemodialysis can take up
nearly 7-8 hours per day for 3-4 times a
week. Consequently, patients frequently
experience “treatment fatigue” and may not
be willing to seek out eye care.
Hemodialysis can be a significant financial
burden for patients, especially since it may
not be covered by insurance. They may
have limited finances available to cover
the cost of eye exams and therefore be
unable to utilize that healthcare service.
Employability can also be an issue for
patients receiving treatment in hemodialysis
centers multiple times a week may be
unable to secure full-time employment.
This can have a significant impact on their
work status and earning potential, further
limiting their access to eye care services
due to financial limitations.

This high-risk hemodialysis population
also faces challenges in obtaining eye care
due in large part to comorbidities that
may be perceived to be more pressing.
These comorbidities include hypertension,
cardiac-related issues, dyslipidemia, and
complications from end-stage renal disease
(e.g., renal osteodystrophy and peripheral
neuropathy). Each of these conditions
requires care from various healthcare
practitioners. Additionally, time and
transportation can be greater challenges
to this patient population than most.
At Wills Eye Hospital, a research team
supported by intramural funds will test
the hypothesis that there is a critical
population health need for improved
access to eye care by hemodialysis
patients leading to undiagnosed diabetic
retinopathy in this population. The study
is a prospective cohort design with a
single patient encounter. It includes
diabetic patients at two hemodialysis
centers; one urban (Walnut Towers, in
downtown Philadelphia) and one suburban
(Marlton, New Jersey). Of the 66 patients
at the Marlton site and 100 at the Walnut
Towers site, it was estimated that 70-100
total had diabetes. The inclusion criteria
enrolled adult diabetes patients who were
able to consent in English. The patients’
demographics, last dilated eye exam, last
podiatry exam, barriers to specialty doctor
examinations, visual function (NEI VFQ-9),
and patients’ pharmacy satisfaction will
all be assessed via a survey. The research
assistant will administer the survey while
the patients are receiving hemodialysis.
Following hemodialysis, the research
assistant will measure visual acuity and
take an undilated fundus photo of each eye
using a non-mydriatic camera. The results

of the eye photographs will be notified to
the patients along with recommendation
of a follow-up eye care in coordination
with the Hemodialysis Director.
The study has the potential to identify a
gap that may exist in a high-risk diabetes
population. Additionally, diagnostic imaging
of the undilated fundus presents a way
to identify hemodialysis patients that
may need earlier treatment. These tools
have overcome the eye-care screening
barriers and help to identify those needing
treatment earlier, lowering the economic
burden to the system and improving
vision outcomes.
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